Aaron Lavinsky, Star Tribune Laura Brod, CEO, RoverMed BioSciences, oversees development of cutting-edge nanotechnology that promises to deliver drugs on a cellular level to fight cancer. A former state legislator and University of Minnesota regent, she uses her leadership and networking skills in the new venture. <\/p>\n
Laura Brod has trod an unusual path into biotech, so perhaps its not surprising that the company she leads is charting an unorthodox route for its ultrasmall precision-medicine technology. Several years ago Brod nearly entered the race for governor following a stint in the Legislature, but she changed course, serving as a regent for the University of Minnesota and becoming CEO of a Minnetonka company called GeneSegues Therapeutics, which was developing medical nanotechnology for cancer. Today Brod is also CEO of a spinoff company based in St. Cloud called RoverMed BioSciences, which is working to apply GeneSegues technology to a broader array of diseases. <\/p>\n
Q: Tell me about your companys technology. <\/p>\n
A: RoverMed has developed a nanotechnology that aims to deliver the next generation of drugs. There are a number of therapeutics being developed by pharmaceutical companies that will never actually impact humans unless they have a precision-targeted delivery technology that is able to bring them directly to the disease cell. And that is what RoverMed does. <\/p>\n
<\/p>\n
See original here: <\/p>\n
Sunday conversation with Laura Brod, CEO or RoverMed BioSciences - Minneapolis Star Tribune<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Aaron Lavinsky, Star Tribune Laura Brod, CEO, RoverMed BioSciences, oversees development of cutting-edge nanotechnology that promises to deliver drugs on a cellular level to fight cancer. A former state legislator and University of Minnesota regent, she uses her leadership and networking skills in the new venture. Laura Brod has trod an unusual path into biotech, so perhaps its not surprising that the company she leads is charting an unorthodox route for its ultrasmall precision-medicine technology. Continue reading